Global Rosacea Treatment Market

Rosacea Treatment Market Size, Share, Growth Analysis, By Type (Erythematotelangiectatic Rosacea, Papulopustular Rosacea), By Drug Class(Antibiotics, Alpha), By Mode of Administration (Topical, Oral), By Region - Industry Forecast 2025-2032

Report ID: SQMIG30L2257 | Region: Global | Published Date: November, 2024
Pages: 194 | Tables: 94 | Figures: 70

Rosacea Treatment Market News

  • A new generic oral rosacea treatment was launched in the United States by Dr. Reddy’s Laboratories in May 2024. Doxycycline Capsules in 40 mg form were launched for treatment of rosacea in adults after they were recently approved by the United States Food and Drug Administration (FDA).
  • New generic oral rosacea treatment was launched by Lupin in the United States in April 2024. The company launched Doxycycline Capsules to provide affordable and accessible rosacea treatment for all.
  • Galderma announced the launch of a new topical product to treat the bumps and blemishes caused by rosacea in June 2022. The new topical EPSOLAY (benzoyl peroxide) Cream, 5% was only made available in the United States following its approval from the FDA.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Rosacea Treatment Market size was valued at USD 1.79 Billion in 2023 and is poised to grow from USD 1.91 Billion in 2024 to USD 3.37 Billion by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

Rosacea treatment companies should primarily invest in the devellopment of a definitive cure for rosecea. Creating awareness regarding rosecea and developing novel treatment products will help rosacea treatment providers stay competitive. Launching new products for management and treatment of rosecea in emerging markets will also help boost revenue generation going forward. 'Gary Pharmaceuticals P Limited ', 'Hovione ', 'Pfizer Inc. ', 'PruGen Pharmaceuticals ', 'Glenmark Pharmaceuticals ', 'Cipla Ltd. ', 'VYNE Therapeutics ', 'Bayer AG ', 'Bausch Health Companies Inc. ', 'AbbVie Inc. ', 'Eckson Labs ', 'Sandoz Spa ', 'Galderma ', 'Abigail Care Pharmaceutical ', 'Aclaris Therapeutics ', 'Colorescience, Inc. ', 'Croda International Plc ', 'Dr. Reddy’s Laboratories Ltd ', 'Leopharma ', 'Lupin'

Incidence of rosacea is increasing around the world as awareness regarding its symptoms increases around the world. Rising number of people living in colder climates is also contributing to the high prevalence of rosacea thereby boosting the demand for rosacea treatment as well.

Use of Natural Ingredients in Rosacea treatment Products: Rosacea treatment companies should focus on using organic and natural ingredients in their products to improve their scope of business. Evolving consumer preferences and rising awareness regarding benefits of treatments with natural ingredients will help this trend create new opportunities for rosacea treatment companies in the long run.

High incidence of rosacea allows the North American region to hold a dominant stance in the global rosacea treatment market landscape. High awareness regarding rosacea, presence of a developed healthcare infrastructure, and rising investments in the R&D of novel rosacea treatments are all factors that will help this region maintain its dominance in the long run. Canada and the United States are estimated to be the top markets for rosacea treatment providers in this region. Increasing drug approvals for rosacea treatment are also estimated to help the high market share of North America over the coming years.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Rosacea Treatment Market

Report ID: SQMIG30L2257

$5,300
BUY NOW GET FREE SAMPLE